Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Giuseppe Viale et al.|Cancer Discovery|2021Cited by 241
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancerMichalina Janiszewska, Kornélia Polyák, Lin Liu et al.|Nature Genetics|2015Cited by 166
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H. Strand, Graham A. Colditz, Belén Rivero‐Gutiérrez et al.|Cancer Cell|2022Cited by 88
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.Otto Metzger, Ian E. Krop, Giuseppe Viale et al.|Journal of Clinical Oncology|2019Cited by 82
Insulin resistance contributes to racial disparities in breast cancer prognosis in US womenEmily J. Gallagher, Nina A. Bickell, Derek LeRoith et al.|Breast Cancer Research|2020Cited by 64